Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1
- PMID: 33754002
- PMCID: PMC7974526
- DOI: 10.7150/jca.52092
Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1
Abstract
Renal cell carcinoma (RCC) is the third most frequent malignancy within urological oncology. Understanding mechanisms of chemoresistance in RCC cell is important for therapy and drug development. We established cisplatin (CDDP) resistant RCC cells by treating cells with increasing concentrations of CDDP. Nodal, an important embryonic morphogen, was increased in RCC/CDDP cells. Targeted inhibition of Nodal via its siRNA or neutralization antibody restored sensitivity of RCC resistant cells to CDDP treatment. It was due to that si-Nodal can decrease expression of P-glycoprotein (P-gp, encoded by ABCB1), one important ATP-binding cassette (ABC) membrane transporter for drug efflux. si-Nodal can decrease the transcription and promoter activity of ABCB1. Mechanistically, si-Nodal can decrease the phosphorylation of p65, which can bind to the promoter of ABCB1 and then trigger its transcription. Further, CDDP treatment decreased the expression of Nodal in culture medium of RCC cells. Collectively, we found that Nodal can regulate chemoresistance of RCC cells via regulating transcription of ABCB1.
Keywords: Nodal; P-gp; RCC; p65; transcription.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
References
-
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. - PubMed
-
- Cai Z, Liu Q. Understanding the Global Cancer Statistics 2018: implications for cancer control. Sci China Life Sci. 2019. - PubMed
-
- Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017;67:507–524. - PubMed
-
- Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA. The Epidemiology of Renal Cell Carcinoma. European Urology. 2011;60:615–621. - PubMed
-
- Grimm MO, Foller S. Immunotherapy for renal cell carcinoma - current status. Aktuelle Urologie. 2018;49:187–191. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
